Clinical Data Maze tumbles despite positive data for kidney disease drug BioPharma DiveInvestors had reservations about data for a drug that could compete with a candidate from Vertex in APOL1-mediated kidney disease.Clinical DataRare DiseaseRead full story pharminent March 25, 2026 (Last updated: March 26, 2026) BioPharma Dive Investors had reservations about data for a drug that could compete with a candidate from Vertex in APOL1-mediated kidney disease. Clinical DataRare DiseaseRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Beam posts positive data on base editing treatment for AATDNext: Wave crashes on obesity drug update; Kodiak’s reboot pays dividends Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
